# Insulet Corporation – Consensus ‘buy’ rating and 45.2% Upside Potential

- Link: https://www.directorstalkinterviews.com/insulet-corporation-consensus-buy-rating-and-45.2-upside-potential/4121145921
- Published: 2024-03-04T13:45:44+00:00
- Author: Charlotte Edwards

**Insulet Corporation** which can be found using ticker (PODD) have now 18 analysts
in total covering the stock. The consensus rating is pointing to ‘buy’. The target
price High/Low ranges between $270.00 and $208.00 and has a mean target at $238.13.
Now with the previous closing price of $164.00 and the analysts are correct then
we can expect a percentage increase in value of 45.2%. The 50 day MA is $197.52 
and the 200 day moving average is $211.46. The market cap for the company is 11.83B.
The stock price for the company is currently $169.25 USD

 The potential market cap would be $17,184,454,023 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 57.57, revenue per share of $24.33
and a 6.09% return on assets.

Insulet Corporation is primarily engaged in the development, manufacture and sale
of its Omnipod System, a continuous insulin delivery system for people with insulin-
dependent diabetes. The Omnipod System includes the Omnipod Insulin Management System(
Classic Omnipod), the Omnipod DASH Insulin Management System (Omnipod DASH), and
the Omnipod 5 Automated Insulin Delivery System (Omnipod 5). The Omnipod System 
features a small, lightweight, self-adhesive disposable tubeless Omnipod device (
Pod) that the user fills with insulin and wears directly on the body for up to three
days at a time, which delivers personalized doses of insulin, and the Personal Diabetes
Manager (PDM) or Controller, a wireless, handheld device that programs the Pod with
the user’s personalized insulin-delivery instructions and wirelessly monitors the
Pod’s operation. The Company sells Pods to Amgen Inc. (Amgen) for use in the Neulasta
Onpro kit, a delivery system for Amgen’s Neulasta.

Share on:
